{"id":"W4210665852","doi":"10.1016/j.lungcan.2022.01.023","title":"Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Afatinib; Medicine; Pembrolizumab; Internal medicine; Lung cancer; Clinical endpoint; Oncology; Adverse effect; Population; Carcinoma; Epidermal growth factor receptor; Surgery; Gastroenterology; Cancer; Gefitinib; Immunotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001924771,0.001531925,0.002594014,0.0004240646,0.0004259079,0.001174648,0.001042066,0.001277903,0.003440897],"category_scores_gemma":[0.0008293687,0.0007506225,0.001477047,0.0004225576,0.0009113581,0.0008567705,0.0004461927,0.00298073,0.001073708],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009604457,"about_ca_system_score_gemma":0.002156117,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008245725,"about_ca_topic_score_gemma":0.002382711,"domain_scores_codex":[0.9994912,0.0002360689,0.00002806045,0.00009282651,0.00004711065,0.0001047076],"domain_scores_gemma":[0.9991632,0.00009027494,0.0001631734,0.00006263488,0.00005218926,0.0004685656],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7479323,0.1097968,0.01416639,0.001038803,0.002094226,0.0003661317,0.0004418845,0.002091325,0.04436988,0.0002081705,0.003008496,0.07448559],"study_design_scores_gemma":[0.6201012,0.3644871,0.01109065,0.00002243747,0.0003312242,0.0002287238,0.00004163861,0.0006141639,0.001740929,0.0000799698,0.001241019,0.00002088141],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935943,0.001242842,0.0004021881,0.0002492762,0.0000782073,0.002915173,0.0006237525,0.00006254375,0.000831775],"genre_scores_gemma":[0.9893561,0.001127146,0.00163537,0.0006972146,0.0001551679,0.003440869,0.001876473,0.00002293256,0.001688635],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003440897,"threshold_uncertainty_score":0.01151091,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007170244930122876,"score_gpt":0.3156310337756659,"score_spread":0.3084607888455431,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}